Drug Profile
Research programme: melanotransferrin conjugated therapeutics - AbbVie/biOasis
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AbbVie
- Developer AbbVie; biOasis Technologies
- Class Drug conjugates
- Mechanism of Action Biological transport stimulants; Transferrin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in CNS-disorders in Canada (Parenteral)
- 19 Jul 2012 Early research in CNS disorders in Canada (Parenteral)